APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human iPSCs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human iPSCs Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchHuman iPSCs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Human iPSCs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Human iPSCs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human iPSCs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human iPSCs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Human iPSCs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human iPSCs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human iPSCs market include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human iPSCs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human iPSCs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human iPSCs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human iPSCs market.

Human iPSCs Segment by Company

Sumitomo Dainippon Pharma

ReproCELL

Pluricell Biotech

Ncardia

Fujifilm Holding Corporation (CDI)

Fate Therapeutics, Inc

Cell Inspire Biotechnology

Astellas Pharma Inc

Human iPSCs Segment by Type

Skin

Blood Cells

Human iPSCs Segment by Application

Regenerative Medicine

Drug Development and Discovery

Academic Research

Toxicity Screening

Others

Human iPSCs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human iPSCs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human iPSCs key companies, revenue, market share, and recent developments.

3. To split the Human iPSCs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human iPSCs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human iPSCs significant trends, drivers, influence factors in global and regions.

6. To analyze Human iPSCs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human iPSCs industry.

Chapter 3: Detailed analysis of Human iPSCs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human iPSCs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human iPSCs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human iPSCs Industry Trends Table 2. Human iPSCs Industry Drivers Table 3. Human iPSCs Industry Opportunities and Challenges Table 4. Human iPSCs Industry Restraints Table 5. Global Human iPSCs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human iPSCs Revenue Share by Company (2021-2026) Table 7. Global Human iPSCs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human iPSCs Key Company Manufacturing Base & Headquarters Table 9. Global Human iPSCs Company, Product Type & Application Table 10. Global Human iPSCs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human iPSCs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Skin Table 15. Significant Companies of Blood Cells Table 16. Global Human iPSCs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Human iPSCs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Human iPSCs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Human iPSCs Sales Value Share by Type (2021-2026) Table 20. Global Human iPSCs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Regenerative Medicine Table 22. Significant Companies of Drug Development and Discovery Table 23. Significant Companies of Academic Research Table 24. Significant Companies of Toxicity Screening Table 25. Significant Companies of Others Table 26. Global Human iPSCs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Human iPSCs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Human iPSCs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Human iPSCs Sales Value Share by Application (2021-2026) Table 30. Global Human iPSCs Sales Value Share by Application (2027-2032) Table 31. Global Human iPSCs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Human iPSCs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Human iPSCs Sales Value Share by Region (2021-2026) Table 34. Global Human iPSCs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Human iPSCs Sales Value Share by Region (2027-2032) Table 36. Global Human iPSCs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human iPSCs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Human iPSCs Sales Value Market Share by Country (2021-2026) Table 39. Global Human iPSCs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Human iPSCs Sales Value Market Share by Country (2027-2032) Table 41. Sumitomo Dainippon Pharma Company Information Table 42. Sumitomo Dainippon Pharma Business Overview Table 43. Sumitomo Dainippon Pharma Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Sumitomo Dainippon Pharma Human iPSCs Product Portfolio Table 45. Sumitomo Dainippon Pharma Recent Development Table 46. ReproCELL Company Information Table 47. ReproCELL Business Overview Table 48. ReproCELL Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. ReproCELL Human iPSCs Product Portfolio Table 50. ReproCELL Recent Development Table 51. Pluricell Biotech Company Information Table 52. Pluricell Biotech Business Overview Table 53. Pluricell Biotech Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pluricell Biotech Human iPSCs Product Portfolio Table 55. Pluricell Biotech Recent Development Table 56. Ncardia Company Information Table 57. Ncardia Business Overview Table 58. Ncardia Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Ncardia Human iPSCs Product Portfolio Table 60. Ncardia Recent Development Table 61. Fujifilm Holding Corporation (CDI) Company Information Table 62. Fujifilm Holding Corporation (CDI) Business Overview Table 63. Fujifilm Holding Corporation (CDI) Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio Table 65. Fujifilm Holding Corporation (CDI) Recent Development Table 66. Fate Therapeutics, Inc Company Information Table 67. Fate Therapeutics, Inc Business Overview Table 68. Fate Therapeutics, Inc Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Fate Therapeutics, Inc Human iPSCs Product Portfolio Table 70. Fate Therapeutics, Inc Recent Development Table 71. Cell Inspire Biotechnology Company Information Table 72. Cell Inspire Biotechnology Business Overview Table 73. Cell Inspire Biotechnology Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Cell Inspire Biotechnology Human iPSCs Product Portfolio Table 75. Cell Inspire Biotechnology Recent Development Table 76. Astellas Pharma Inc Company Information Table 77. Astellas Pharma Inc Business Overview Table 78. Astellas Pharma Inc Human iPSCs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Astellas Pharma Inc Human iPSCs Product Portfolio Table 80. Astellas Pharma Inc Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Human iPSCs Product Image Figure 2. Global Human iPSCs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human iPSCs Market Size (2021-2032) & (US$ Million) Figure 4. Global Human iPSCs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Skin Image Figure 8. Blood Cells Image Figure 9. Global Human iPSCs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Human iPSCs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Human iPSCs Sales Value Share by Type (2021-2032) Figure 12. Regenerative Medicine Image Figure 13. Drug Development and Discovery Image Figure 14. Academic Research Image Figure 15. Toxicity Screening Image Figure 16. Others Image Figure 17. Global Human iPSCs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human iPSCs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human iPSCs Sales Value Share by Application (2021-2032) Figure 20. Global Human iPSCs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Human iPSCs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Human iPSCs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Human iPSCs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Human iPSCs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Human iPSCs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Human iPSCs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Human iPSCs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Human iPSCs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Human iPSCs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Human iPSCs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Human iPSCs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Human iPSCs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Human iPSCs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Human iPSCs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Skin
  • Blood Cells
Applications
  • Regenerative Medicine
  • Drug Development and Discovery
  • Academic Research
  • Toxicity Screening
  • Others
Companies covered
  • Sumitomo Dainippon Pharma
  • ReproCELL
  • Pluricell Biotech
  • Ncardia
  • Fujifilm Holding Corporation (CDI)
  • Fate Therapeutics, Inc
  • Cell Inspire Biotechnology
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human iPSCs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human iPSCs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human iPSCs Market Dynamics
  1. 2.1 Human iPSCs Industry Trends
  2. 2.2 Human iPSCs Industry Drivers
  3. 2.3 Human iPSCs Industry Opportunities and Challenges
  4. 2.4 Human iPSCs Industry Restraints
3 Human iPSCs Market by Company
  1. 3.1 Global Human iPSCs Company Revenue Ranking in 2025
  2. 3.2 Global Human iPSCs Revenue by Company (2021-2026)
  3. 3.3 Global Human iPSCs Company Ranking (2024-2026)
  4. 3.4 Global Human iPSCs Company Manufacturing Base and Headquarters
  5. 3.5 Global Human iPSCs Company Product Type and Application
  6. 3.6 Global Human iPSCs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human iPSCs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human iPSCs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human iPSCs Market by Type
  1. 4.1 Human iPSCs Type Introduction
  2. 4.1.1 Skin
  3. 4.1.2 Blood Cells
  4. 4.2 Global Human iPSCs Sales Value by Type
  5. 4.2.1 Global Human iPSCs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human iPSCs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Human iPSCs Sales Value Share by Type (2021-2032)
5 Human iPSCs Market by Application
  1. 5.1 Human iPSCs Application Introduction
  2. 5.1.1 Regenerative Medicine
  3. 5.1.2 Drug Development and Discovery
  4. 5.1.3 Academic Research
  5. 5.1.4 Toxicity Screening
  6. 5.1.5 Others
  7. 5.2 Global Human iPSCs Sales Value by Application
  8. 5.2.1 Global Human iPSCs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Human iPSCs Sales Value by Application (2021-2032)
  10. 5.2.3 Global Human iPSCs Sales Value Share by Application (2021-2032)
6 Human iPSCs Regional Value Analysis
  1. 6.1 Global Human iPSCs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human iPSCs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human iPSCs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human iPSCs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human iPSCs Sales Value (2021-2032)
  7. 6.3.2 North America Human iPSCs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human iPSCs Sales Value (2021-2032)
  10. 6.4.2 Europe Human iPSCs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human iPSCs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human iPSCs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human iPSCs Sales Value (2021-2032)
  16. 6.6.2 South America Human iPSCs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human iPSCs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human iPSCs Sales Value Share by Country, 2025 VS 2032
7 Human iPSCs Country-level Value Analysis
  1. 7.1 Global Human iPSCs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human iPSCs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human iPSCs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human iPSCs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human iPSCs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human iPSCs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human iPSCs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human iPSCs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human iPSCs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human iPSCs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human iPSCs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human iPSCs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human iPSCs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human iPSCs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human iPSCs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human iPSCs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human iPSCs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human iPSCs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human iPSCs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human iPSCs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human iPSCs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human iPSCs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human iPSCs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human iPSCs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human iPSCs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human iPSCs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human iPSCs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human iPSCs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human iPSCs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human iPSCs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human iPSCs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human iPSCs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human iPSCs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human iPSCs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human iPSCs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human iPSCs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human iPSCs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human iPSCs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human iPSCs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human iPSCs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human iPSCs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human iPSCs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human iPSCs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human iPSCs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human iPSCs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human iPSCs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human iPSCs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human iPSCs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human iPSCs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human iPSCs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human iPSCs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human iPSCs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human iPSCs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human iPSCs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human iPSCs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human iPSCs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human iPSCs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human iPSCs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human iPSCs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human iPSCs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human iPSCs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human iPSCs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human iPSCs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human iPSCs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human iPSCs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human iPSCs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human iPSCs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human iPSCs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human iPSCs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human iPSCs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human iPSCs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human iPSCs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human iPSCs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human iPSCs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human iPSCs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human iPSCs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human iPSCs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human iPSCs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human iPSCs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human iPSCs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human iPSCs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human iPSCs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human iPSCs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human iPSCs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human iPSCs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human iPSCs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human iPSCs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human iPSCs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sumitomo Dainippon Pharma
  2. 8.1.1 Sumitomo Dainippon Pharma Company Information
  3. 8.1.2 Sumitomo Dainippon Pharma Business Overview
  4. 8.1.3 Sumitomo Dainippon Pharma Human iPSCs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
  6. 8.1.5 Sumitomo Dainippon Pharma Recent Developments
  7. 8.2 ReproCELL
  8. 8.2.1 ReproCELL Company Information
  9. 8.2.2 ReproCELL Business Overview
  10. 8.2.3 ReproCELL Human iPSCs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ReproCELL Human iPSCs Product Portfolio
  12. 8.2.5 ReproCELL Recent Developments
  13. 8.3 Pluricell Biotech
  14. 8.3.1 Pluricell Biotech Company Information
  15. 8.3.2 Pluricell Biotech Business Overview
  16. 8.3.3 Pluricell Biotech Human iPSCs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pluricell Biotech Human iPSCs Product Portfolio
  18. 8.3.5 Pluricell Biotech Recent Developments
  19. 8.4 Ncardia
  20. 8.4.1 Ncardia Company Information
  21. 8.4.2 Ncardia Business Overview
  22. 8.4.3 Ncardia Human iPSCs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ncardia Human iPSCs Product Portfolio
  24. 8.4.5 Ncardia Recent Developments
  25. 8.5 Fujifilm Holding Corporation (CDI)
  26. 8.5.1 Fujifilm Holding Corporation (CDI) Company Information
  27. 8.5.2 Fujifilm Holding Corporation (CDI) Business Overview
  28. 8.5.3 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
  30. 8.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
  31. 8.6 Fate Therapeutics, Inc
  32. 8.6.1 Fate Therapeutics, Inc Company Information
  33. 8.6.2 Fate Therapeutics, Inc Business Overview
  34. 8.6.3 Fate Therapeutics, Inc Human iPSCs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
  36. 8.6.5 Fate Therapeutics, Inc Recent Developments
  37. 8.7 Cell Inspire Biotechnology
  38. 8.7.1 Cell Inspire Biotechnology Company Information
  39. 8.7.2 Cell Inspire Biotechnology Business Overview
  40. 8.7.3 Cell Inspire Biotechnology Human iPSCs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
  42. 8.7.5 Cell Inspire Biotechnology Recent Developments
  43. 8.8 Astellas Pharma Inc
  44. 8.8.1 Astellas Pharma Inc Company Information
  45. 8.8.2 Astellas Pharma Inc Business Overview
  46. 8.8.3 Astellas Pharma Inc Human iPSCs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
  48. 8.8.5 Astellas Pharma Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst